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Summary Based on data from the Nordic cancer registries, time-related trends in incidence of Kaposi's
sarcoma (KS) were analysed in four ethnically similar populations before the AIDS epidemic. Data were
available for different time periods in Denmark (1970-79), Sweden (1958-79), Finland (1953-79) and
Norway (1953-79). KS was more common among men than among women aged 60 years or more, whereas no
differences were observed for younger persons. The incidence of KS differed significantly between the four
countries (P=0.0001); Sweden having the highest and Denmark the lowest rates. Similarly, regional differences
in incidence were observed within Sweden, rates being higher in the northern than in the southern areas
(Ptrend =0.002). Overall, in Nordic men the world standardised incidence rose from 0.5/1 000 000 person -years
in the period 1953-57 to 1.8/1 000 000 person-years in 1978-79; in Nordic women, the corresponding rates
were 0.2/1 000 000 person-years and 0.8/1 000 000 person-years respectively. The rate of increase was similar
in Sweden, Finland and Norway (P=0.14), whereas the short period of observation in Denmark precluded
precise assessment of time-related incidence trends. These observations cannot be explained by registrational
procedures or known risk factors for KS, and argue that environmental factors play an important role in the
development of the disease.
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One of the hallmarks of the onset of the AIDS epidemic in
the early 1980s was the sudden increase in incidence of
Kaposi's sarcoma (KS). This increase in the occurrence of a
previously exceedingly rare condition naturally prompted a
renewed interest in its epidemiology, including assessment of
the incidence before the AIDS epidemic. From such studies,
it became evident that the incidence of KS differed
considerably between European countries. Thus, even taking
the use of different standard populations into account, the
rates reported for Italy, 10.5/1 000 000 person-years and
2.7/1 000 000 person-years in men and women respectively
(Geddes et al., 1994), by far exceeded the rates reported for
England and Wales, being 0.14/1 000 000 person-years in
both men and women (Grulich et al., 1992).
Because of the rareness of KS, the quality of registry data
is critically dependent on the reporting infrastructure. This,
and the fact that only a few countries have longer traditions
for cancer registrations, are presumably the main reasons
why only a few reports have presented data for more than
one decade before the AIDS epidemic. Accordingly, only a
little is known about the time-related incidence trends of KS.
Interestingly, however, at least one study suggested that the
incidence of KS increased before the AIDS epidemic (Dictor
and Attewell, 1988).
The objective of the present study was to provide further
information about the epidemiology of KS in four ethnically
similar Nordic populations in the pre-AIDS era. To this
purpose, we took advantage of the long history and high
quality of cancer registration in the Nordic countries to
investigate time-related trends in classical KS and to provide
incidence rates from a large north European area, populated
by 22 million people in 1980.
Materials and methods
The structures of the Nordic cancer registries have been
described in detail elsewhere (Hakulinen et al., 1986). In
brief, the registries record all cases of cancers in the national
populations using almost identical procedures and classifica-
tions. The ascertainment rate of the registries is high,
ensuring close to 100% completeness (Hakulinen et al.,
1986). To avoid potential misclassification between classical
KS and AIDS-KS, the present study was restricted to the
period before 1980.
In Denmark, KS has been registered as a separateentity only
since 1978. Cases for the period 1970-77 were sought in the
Danish Cancer Registry under codes for potentially relevant
skin cancers and sarcomas according to a modified version of
the seventh revision of the International Classification of
Diseases (ICD-7). Cases diagnosed in 1978 and 1979 were
identified by searches under codes for KS and for morpholo-
gically closely related tumours, including angiosarcomas,
according to the International Classification of Diseases,
Oncology (ICD-O). In addition to these searches, cases were
manually sought in all Danish pathology departments,
applying a similar search strategy. Finally, in questionable
cases the search for KS included examination of histological
slides and/or scrutiny of the original pathology reports.
In the Swedish Cancer Registry, KS has been registered
separately since 1958. As part of a previous study (Dictor and
Attewell, 1988), all notifications of KS, reported either
originally as KS or erroneously as angiosarcomas, were
identified and validated.
In Norway, KS has been registered since 1953. As part of
a previous report (Harvei et al., 1990), cases of KS were
sought under the original KS code as well as under the codes
for angiosarcomas. In all cases, the histopathological
descriptions were scrutinised.
The Finnish Cancer Registry has registered KS separately
since the beginning of 1953. All cases of KS were sought
under their original codes. Considering the high reliability of
the Finnish Cancer Registry in general (Teppo et al., 1994),
data were accepted without further scrutiny.
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Statistical methods
The material was divided into five year intervals (1953-57,
1958-62, 1973-77, 1978-1979) and five year age groups.
Age- and sex-specific incidence rates were calculated for each
country and for the four countries combined, using
population data from the respective national bureaux of
statistics. Based on these rates, age-adjusted incidence rates
were calculated by means of direct standardisation, using the
world standard population as reference (Breslow and Day,
1980).
Multivariate modelling of the incidence rates with respect
to sex, age, calendar time and country was performed. For
this purpose, the patient material was divided into two
groups according to the age of diagnosis, i.e. patients
younger than 60 years and those 60 years or older. The
modelling was performed by means of Poisson regression
analysis using the backward elimination procedure (Klein-
baum et al., 1988).
Finally, in order to evaluate local differences in the
incidence of KS, Swedish patients were divided into six
groups corresponding to the six regional cancer registries.
Trends in incidence from south to north were analysed by
means of Poisson regression analysis (Kleinbaum et al.,
1988), attributing the respective latitudes of the centres of
population to each of the six regions (Table III).
Results
A total of 723 cases of KS, 481 in men and 242 in women,
were identified. The distribution of the cases with regard to
geography, sex and age is given in Tables I and II.
In both sexes the incidence of KS increased with age
(Table II), and overall, the incidence of KS was higher
among men than among women (Figure 1). The male excess
was primarily restricted to the age group >60 years
(P<0.0001), whereas the male-female rate ratio did not
differ significantly from unity among patients younger than
60 years (P=0.26).
Table I Distribution of cases of Kaposi's sarcoma by sex, age and
country
Men Women
<60 >60 Total <60 >60 Total
Country Period years years years years
Sweden 1958-79 34 284 318 22 123 145
Finland 1953-79 8 32 40 14 25 39
Norway 1953-79 13 97 110 8 41 49
Denmark 1970-79 3 10 13 1 8 9
All 58 423 482 45 197 242
During the study period, the incidence of KS differed
significantly between the four countries (Figure 1). Although
not constantly, the highest incidence rates in general were
observed in Sweden, followed by Norway, Finland and
Denmark. In the period 1973-77, for example, the world
standardised incidence of KS among men was 0.2/1 000 000
person-years in Denmark, 1.0/1 000 000 person-years in
Finland, 1.9/1 000 000 person-years in Norway, and 2.6/
1 000 000 person-years in Sweden. Among women the
corresponding rates were 0.1/1 000000 person-years in
Denmark, 0.8/1 000000 person-years in Finland, 0.9/
1000000 person-years in Norway and 0.8/1 000000 per-
son-years in Sweden. These differences in incidence were
evident throughout most of the study period and varied only
insignificantly between Sweden, Norway and Finland
(P=0.14). Contrary to this, the time-related variation in
incidence differed significantly between Denmark and the
other countries (P=0.03).
Apart from the intra-Nordic differences in incidence,
regional differences in the incidence of KS were also
observed within Sweden, the incidence being significantly
higher in the northern than in the southern parts of Sweden
(test for linearity: X2=6.96, 3 d.f., P=0.07; test for linear
trend: X2=9.62, 1 d.f., P=0.0019) (Table III).
Overall, the incidence of KS in the Nordic area as a whole
increased during the study period. Thus, between 1958-62
and 1978-79 the world standardised incidence of KS in the
Nordic area increased from 1.1/1 000 000 person-years in
men and 0.2/1 000 000 person-years in women (three
countries contributing) to 1.8/1 000 000 person-years in
men and 0.7/1 000 000 person-years in women (four
countries contributing) (Figure 1). The increase was
observed in both the young (<60 years) and the old (>360
years) age group (Table II). The rate of increase was similar
in the three countries with the longest periods of observation,
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Table II Number of cases and age-specific incidence rates (per
1 000000 person-years) for the entrire Nordic area
Women Men
1953-67 1968- 79 1953-67 1968- 79
Number Rate Number Rate Number Rate Number Rate
0-9 - 1 0.06 1 0.05
10- 19 - - - - - 2 0.10
20-29 - - 3 0.16 1 0.08 9 0.44
30-39 1 0.08 7 0.44 1 0.08 4 0.24
40-49 6 0.45 8 0.55 4 0.31 6 0.41
50-59 5 0.41 15 0.99 11 0.97 18 1.25
60-69 10 1.08 34 2.47 26 3.33 58 4.87
70-79 16 2.93 62 6.77 55 13.50 134 20.21
80+ 8 4.23 67 18.75 33 25.53 117 55.03
All 46 0.46a 196 1.54a 132 1.36a 349 2.80a
aCrude incidence rates per 1 000000 person years.
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Figure 1 World standardised incidence rates of Kaposi's
sarcoma in the Nordic countries.
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Table III Number of cases and crude incidence rates (per 1 000000
person-years) in six Swedish areas
Crude incidence
Area (latitude) Number of cases rates
Lund-Malmo (55.5) 68 2.2
Link6ping (58) 48 2.5
Goteborg (58) 92 3.2
Stockholm (59) 89 2.8
Uppsala-Orebro (59.5) 91 2.3
Umea (64) 75 4.0
Ptrend =0.0019.
i.e. Sweden, Norway and Finland, whereas the short period
of observation in Denmark precluded a conclusive assessment
of trends in the time-related incidence variation.
Discussion
The analyses demonstrated that significant differences existed
in the incidence of KS between the Nordic countries before
the onset of the AIDS epidemic. Differences with respect to
diagnostic criteria, misclassification and under-reporting may
contribute to the intra-Nordic variation, but in a Nordic
context such factors presumably are of limited significance.
Thus, there is an intense communication on both the
educational and scientific level between specialists from the
four countries, tending to eliminate differences in the
interpretation of cases with respect to diagnostic criteria.
Furthermore, both the Swedish, Norwegian and the Danish
materials arose through careful scrutiny of notifications and
registrations. Likewise, it seems reasonable to assume that the
high standard of the Finnish Cancer Registry in general
would also apply to the registration of KS (Teppo et al.,
1994). Rather, a number of observations indicate that the
incidence variation is real. This includes the consistency of
the differences in KS incidence between the three countries
contributing the majority of cases, the very low incidence of
KS in Denmark compared with the other countries, along
with the geographical differences in Sweden.
Additional evidence of considerable variation in KS
incidence comes from other studies of KS in the period
before the AIDS epidemic. Apart from the previously
mentioned studies from England and Wales (Grulich et al.,
1992) and Italy (Geddes et al., 1994), age-adjusted rates have
been reported from the US for the period 1973-79 (2.9/
1 000 000 person-years in men and 0.7/1 000 000 person-
years in women) (Biggar et al., 1984) and from Australia for
the period 1972-82 (0.65/1 000 000 person-years in men
and 0.29/1 000 000 person-years in women) (Kaldor et al.,
1994). Moreover, extremes such as complete absence of KS in
the Swiss canton of Vaud in the period 1974-82 (Levi et al.,
1993), and crude rates of 16/1 000 000 person-years in men
and women in Sardinia in the period 1977-82 (Cerimele et
al., 1984) have also been published. While these differences
may be more difficult to interpret, it seems unlikely that they
should result from differences in registrational procedures or
standardisation alone (Geddes et al., 1994).
Unlike the above-mentioned studies, the long tradition of
cancer registration in the Nordic countries allowed for
evaluation of time-related incidence trends. Accordingly, it
was demonstrated that the incidence of KS increased in the
Nordic countries before the AIDS epidemic. This increase
cannot easily be explained. The incidence of KS increased
with age and, given the general improvements in health care
for elderly persons that have taken place during the study
period, part of the increase among those aged 60 years or
more may be accounted for by diagnostic improvements.
Even though only two cases of KS were found among 5692
Scandinavian renal transplant recipients in a recent study
(Birkeland et al., 1995), iatrogenic immune suppression, such
as in organ transplant recipients, remains a well-established
risk factor for KS (Kinlen, 1982; Penn, 1983; Quibini et al.,
1988). Similarly, systemic corticosteroid treatment has been
suggested to confer an increased risk of KS in non-transplant
recipients (Klepp et al., 1978). Owing to the descriptive
nature of our register-based study, we are unable to estimate
to what extent, if any, iatrogenic immune suppression has
contributed to the observed increase in the incidence of KS in
the Nordic countries. Previous studies have demonstrated an
increased risk of KS in persons of certain ethnicities, i.e.
persons from Central and East Africa, Eastern Europe or
Mediterranean countires and those of Jewish descent (Laor
and Schwartz, 1979; Friedman-Birnbaum et al., 1990; Kaldor
et al., 1994; Grulich et al., 1992; DiGiovanna and Safai,
1981). Although an excess of immigrants has been observed
among Danish patients with non-AIDS-related KS in the
period 1970-92 (Hjalgrim et al., 1996), less than 5% of the
Swedish and Norwegian cases of KS were diagnosed in
persons of foreign descents (Dictor and Attewell, 1988;
Harvei et al., 1990). Thus, differences in immigration patterns
within the Nordic area can explain neither the differences in
incidence nor the observed increase.
Support for an infectious aetiology in KS pathogenesis is
accumulating (Beral et al., 1990, 1992). DNA sequences from
a Herpesvirus have recently been detected in both AIDS-
related and classical KS lesions (Su et al., 1995; Chang et al.,
1994) and culturing of the virus has been reported (Renne et
al., 1996). If involved in the aetiology of KS, differences in
the prevalence of the virus with respect to time and place or
in cofactors determining disease progression offer a plausible
explanation for the observed geographic variation and the
observed increase in KS incidence. The virus has been
isolated in plasma (Whitby et al., 1995) and, in theory, it
should be able to survive Cohn fractionation in the process of
gamma globulin production. Although purely speculative, we
note that during the study period, the consumption of
gamma globulin increased considerably in the Nordic
countries and that sources of gamma globulin differed
between the countries. Thus, while gamma globulin in
Denmark was based on plasma from Danish donors, gamma
globulin used in the other countries was to a large extent
either imported or produced from imported plasma, including
large imports from KS-endemic areas, such as Italy.
In conclusion, the incidence of registered cases of classical
KS increased in the Nordic area before the AIDS epidemic.
In the early years of the study period, significantly improved
diagnostic tools and hardly measurable changes in the
classification of this rare tumour may have played a role.
What should be emphasised, however, is the remarkable
geographical variation in KS incidence figures that exist
between ethnically quite similar populations, such as the
Nordic countries.
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